简化多替拉韦单药治疗在原发性HIV感染早期启动cART患者中的非劣效性随机对照试验
EARLY-SIMPLIFIED是一项随机、开放标签、多中心非劣效性试验,纳入在原发HIV-1感染后180天内启动cART且HIV-1 RNA<50 copies/mL持续至少48周的患者,按2:1随机分配至多替拉韦50 mg每日一次单药治疗组或继续cART组。第48周符合方案人群分析显示,多替拉韦单药组67/67(100%)与cART组32/32(100%)均达到病毒学应答,差异0.00%(95%CI -100%至4.76%),在预设非劣效界值10%下证明非劣效。
要点
- 原发HIV感染早期启动cART且病毒抑制≥48周者,多替拉韦单药非劣于继续cART。
- 第48周两组病毒学应答率均为100%,差异0.00%(95%CI -100%至4.76%)。
- 未来简化治疗研究应按HIV感染时间和首次cART启动时间分层。
核心结论
- 在原发HIV-1感染期间启动cART且HIV-1 RNA<50 copies/mL至少48周的患者中,每日一次多替拉韦单药治疗第48周病毒学应答非劣于继续cART。
研究设计与样本
- EARLY-SIMPLIFIED为随机、开放标签、多中心非劣效性试验,共随机101例患者,多替拉韦单药组68例,继续cART组33例。
主要发现
- 第48周符合方案人群中,多替拉韦单药组67/67(100%)与cART组32/32(100%)达到HIV-1 RNA<50 copies/mL,差异0.00%(95%CI -100%至4.76%)。
- 该结果在预设非劣效界值10%下证明多替拉韦单药非劣效。
关键数值与推荐
- 主要疗效终点为第48周或之前HIV-1 RNA<50 copies/mL的患者比例,非劣效界值为10%。
- 入组条件为原发HIV-1感染 documented后<180天启动cART,且HIV-1 RNA<50 copies/mL持续至少48周。
- 多替拉韦单药剂量为50 mg每日一次。
临床怎么用
- 对于原发HIV感染早期启动cART且已稳定病毒抑制至少48周的患者,可考虑简化至多替拉韦单药治疗,但需注意此为试点研究。
- 临床决策时应结合感染时间和cART启动时间进行分层评估。
局限性
- 本研究为试点研究,样本量较小(共101例)。
- 研究为开放标签设计。
- 结论需在更大规模研究中验证,未来研究应按HIV感染时间和cART启动时间分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who start combination antiretroviral therapy (cART) during primary human immunodeficiency virus type 1 (HIV-1) infection show a smaller HIV-1 latent reservoir, less immune activation, and less viral diversity compared to patients who start cART during chronic infection. We conducted a pilot study to determine whether these properties would allow sustained virological suppression after simplification of cART to dolutegravir monotherapy. METHODS: EARLY-SIMPLIFIED is a randomized, open-label, noninferiority trial. Patients who started cART <180 days after a documented primary HIV-1 infection and had an HIV-1 RNA <50 copies/mL plasma for at least 48 weeks were randomized (2:1) to monotherapy with dolutegravir 50 mg once daily or to continuation of cART. The primary efficacy endpoint was the proportion of patients with <50 HIV-1 RNA copies/mL on or before week 48; noninferiority margin 10%. RESULTS: Of the 101 patients randomized, 68 were assigned to simplification to dolutegravir monotherapy and 33 to continuation of cART. At week 48 in the per-protocol population, 67/67 (100%) had virological response in the dolutegravir monotherapy group vs 32/32 (100%) in the cART group (difference, 0.00%; 95% confidence interval, -100%, 4.76%). This showed noninferiority of the dolutegravir monotherapy at the prespecified level. CONCLUSION: In this pilot study consisting of patients who initiated cART during primary HIV-1 infection and had <50 HIV-1 RNA copies/mL for at least 48 weeks, monotherapy with once-daily dolutegravir was noninferior to cART. Our results suggest that future simplification studies should use a stratification according to time of HIV infection and start of first cART. CLINICAL TRIALS REGISTRATION: NCT02551523.
引用
- Braun DL, Turk T, Tschumi F, et al. Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clin Infect Dis. 2019. PMID: 30601950. doi:10.1093/cid/ciy1131
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。